Altre lingue Cybin Inc.

Azioni

CLXPF

CA23256X4075

Biotecnologia

Mercato chiuso - Nyse Altri mercati azionari 22:00:00 11/07/2025			Variaz. 5gg	Var. 1 gen.
7,640 ^USD	+0,53%		-3,78%	-13,38%

01/07	Principali Titoli in Rialzo a Metà Giornata	MT
01/07	Cybin Firma un Accordo con High Trail per Emissione di Obbligazioni Convertibili fino a 500 Milioni di Dollari	MT

Altre lingue

Cybin : Corporate Presentation July 2025	01/07
Top Midday Gainers	01/07
Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures	01/07
Cybin Signs Deal With High Trail to Sell, Issue Up to $500 Million Convertible Debentures	01/07
Cybin Inc. Reports Earnings Results for the Full Year Ended March 31, 2025	01/07
Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights	01/07
Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures	01/07
Cybin Inc. announced that it expects to receive $500 million in funding from High Trail Special Situations LLC	30/06
Cybin Inc. Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics	13/06
Cybin Provides Corporate Update, Highlights Positive Regulatory Signals For Psychedelic Therapeutics	13/06
Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics	13/06
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference	12/06
Cybin to Participate in the 2025 Psychedelic Science Conference	11/06
Cybin Granted Additional US Patent for Potential Anxiety Disorder Treatments	03/06
Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder	03/06
Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025	22/05
Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics	20/05
Cybin Says Thermo Fisher Scientific to Offer US-Based Manufacturing for Its Depressive Disorder Program	15/05
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder	15/05
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase	14/05
Cybin Inc. Announces Additional U.S. Patent Supporting Its Cyb003 Therapy Program in Phase 3 Development for Major Depressive Disorder	08/05
Cybin Announces Additional U.S. Patent Supporting Its CYB003 Breakthrough Therapy Program In Phase 3 Development For Major Depressive Disorder	08/05
Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder	08/05
Cybin to Participate at the 28th Annual Milken Institute Global Conference	01/05
Cybin Says Second Phase 3 Study Embrace Expected To Begin Mid-2025	23/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Trascrizioni Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Cybin Inc.

Azioni

CLXPF

CA23256X4075

Biotecnologia

Altre lingue

Filtri